Affiliate disclosure: Some links on this page are affiliate links — we may earn a commission if you buy through them, at no extra cost to you. This doesn't affect our editorial independence. We test every product ourselves.

Where AI Meets Drug Discovery

Tracking the companies, deals, and breakthroughs turning algorithms into medicine. Pipeline data updated weekly.

0 Market Size (2026, $B)
0 Annual Growth Rate (%)
0 Active AI Drug Trials
0 Avg Dev Cost, Traditional ($B)

Drug Pipeline Tracker

Real-time view of AI-designed drugs advancing through clinical stages globally.

Discovery

AI target identification

Preclinical

Lab validation

Phase I/II

Human trials underway

Phase III/Approval

Regulatory pathway

INS018_055
Idiopathic Pulmonary Fibrosis (IPF)
Phase II

Insilico Medicine. Advanced AI-designed molecule. 255M Series D funding.

GTAEXS617
Oncology (Solid Tumors)
Phase I

Exscientia. First fully AI-designed drug in humans. Oxford spinoff.

REC-994
Inflammatory Diseases
Phase I/II

Recursion. Computer vision platform for biology. NYSE: RXRX.

BEN-8744
Neurological Disorders
Phase I

BenevolentAI. London-based. Euronext-listed platform.

Major Partnerships & Funding

High-value collaborations and Series funding rounds reshaping the landscape.

Date Partners Deal Value Focus
2024 Isomorphic Labs + Eli Lilly $1.7B Drug design & discovery platform
2024 Isomorphic Labs + Novartis $1.2B Small molecule discovery
2024 Recursion + NVIDIA Partnership GPU compute for drug discovery
2023 Insilico Medicine Series D $255M AI drug development platform
2023 Exscientia Series C $200M+ AI-designed drug advancement
2022 BenevolentAI IPO £300M+ Euronext listing, public markets

Market Intelligence

2026 biotech AI landscape snapshot and strategic metrics.

Global AI Drug Discovery Market

$4B

Valued at 2026, with accelerating growth trajectory

CAGR (2020-2026)

40%+

Year-over-year expansion rate

UK Biotech Sector

6.3K

Active companies, £94B+ market cap

Active AI Drug Trials

100+

Globally in clinical stages

Traditional Drug Dev Cost

$2.6B

Average per approved drug

AI-Assisted Est. Cost

$300-500M

Potential reduction with AI

Key Companies Shaping AI Drug Discovery

Leading platforms and their strategic positions in the AI-driven biotech ecosystem.

Isomorphic Labs
DeepMind's drug discovery spinoff. $2.9B in partnerships with Eli Lilly and Novartis. Arguably the most advanced AI drug design platform leveraging AlphaFold breakthroughs.
Recursion
NYSE: RXRX. $750M+ raised. Using computer vision and deep learning to decode biology at scale. NVIDIA partnership for GPU-accelerated discovery.
BenevolentAI
London-based, Euronext-listed. Built the AI that identified baricitinib for COVID-19 treatment. Expanding pipeline with proprietary AI drug discovery engine.
Exscientia
Oxford spinoff. First company to put an AI-designed drug (GTAEXS617) into clinical trials. Proving AI-to-clinic acceleration is achievable.
Insilico Medicine
INS018_055 in Phase II for IPF. $255M Series D. AI-native drug design using generative models. Global clinical trials across major markets.
DeepMind (AlphaFold)
Protein folding breakthrough: 200M+ structures predicted. Foundation layer for all modern AI drug discovery. Transformed target identification speed.

Latest Insights

Recent breakthroughs and strategic developments in AI drug discovery.

AlphaFold 3 vs RoseTTAFold: The Protein Folding Race Explained
DeepMind and Baker Lab push boundaries. Implications for structure-based drug design and timeline compression in discovery phase.
Is AI Drug Discovery Actually Faster? The Data So Far
Analysis of Exscientia, Insilico, and Isomorphic milestones. Timelines reduced from 5-10 years to 2-3 years in select cases.
UK Biotech AI Investment Guide 2026
Funding landscape, regulatory pathways (MHRA/EMA), and venture capital concentration in Oxford, Cambridge, and London hubs.
The 10 Most Promising AI-Designed Drugs in Clinical Trials
Detailed pipeline analysis including INS018_055, GTAEXS617, REC-994, and emerging candidates. Risk, indication, and timeline summary.

Free: AI Drug Discovery Pipeline Tracker

Monthly updates on Phase I-III AI-discovered compounds. 40+ molecules tracked.

No spam. Unsubscribe anytime. We respect your data.

Subscribe to Pipeline Updates Shop Now →